Company* (Country; Symbol) |
Company* (Country; Symbol) |
Product |
Terms/Details (Date) |
| | |||
Acambis plc (UK; ACAM; LSE:ACM) |
Cangene Corp. (Canada; TSE:CNJ) |
Cangene's vaccinia immune globulin product |
Agreement to market the product in markets outside North America and Israel (3/11) |
|
|
||
Aclara BioSciences Inc. (ACLA) |
Amersham Biosciences (unit of Amersham plc; UK; NYSE:AHM; LSE:OSE) |
MegaBACE DNA Analysis Systems in combination with Aclara's eTag Assay System |
Joint marketing and services agreement in which Amersham will continue to sell and support MegaBACE as a stand-alone sys- tem, but also for use with the Aclara eTag assay chemistries and applications (4/2) |
|
|
||
Advion Biosciences Inc.* |
Thermo Electron Corp. (NYSE:TMO) |
The NanoMate 100 Automated Nanoelectrospray robotic system and ESI Chip |
Nonexclusive agreement to co-market their products to life sciences researchers (3/10) |
|
|
||
AEterna Laboratories Inc. (Canada; AELA; TSE:AEL) |
LG Life Sciences Ltd.* (affiliate of the LG Group; Korea) |
Neovastat |
Agreement for LG Life Sciences to market Neovastat in Korea; AEterna will gain an up-front payment, as well as milestone pay- ments and a return on manufacturing and sales (3/26) |
|
|||
Agilent Technologies Inc. (NYSE:A) |
Pierce Biotechnology Inc.*(unit of Perbio Science AB) |
Agilent 2100 bioanalyzer, Protein 200 Plus and Protein 50 LabChip kits, as well as Pierce protein reagents and consumables |
Marketing agreement that will focus on protein application areas in which both companies have existing products that can be combined (4/8) |
|
|||
Agilent Technologies Inc.(NYSE:A) |
Qiagen NV (the Netherlands; QGENF) |
Agilent 2100 bioanalyzer and LabChip kits, as well as Qiagen's consumables and instruments for the separation, purification and handling of nucleic acids and proteins |
Companies entered a nonexclusive agreement to jointly market their products (3/27) |
|
|||
Aptamera Inc.* |
Assay Designs Inc.* |
OncoMarker IHC kit |
Assay Designs will market Aptamera's OncoMarker IHC kit, which identifies tumor cells by detecting the presence of a specific protein on the cell surface (3/28) |
|
|||
Bioxel Pharma Inc. (Canada;VSE:BIP) |
Atlantis BioActives Corp.* (Canada) |
Intermediate taxanes extracted from Bioxel's Canada yew biomass |
The supply agreement is for the production of intermediate taxanes, including paclitaxel 10-DAB and DHB, from the Canada yew biomass or crude extracts from that biomass (3/12) |
|
|||
Charles River Laboratories International Inc. (NYSE:CRL) |
Xenogen Biosciences* (subsidiary of Xenogen Corp.) |
Xenogen Biosciences' genomic services |
Charles River will market the services to the clients of its Transgenic Services business (4/7) |
|
|
||
CollaGenex Pharmaceuticals Inc. (CGPI) |
Sirius Laboratories Inc.* |
Pandel and AVAR |
Companies will jointly promote in the U.S. CollaGenex's Pandel and Sirius' AVAR product lines (3/20) |
|
|||
Excell Biotech* (Scotland) |
Resistentia Pharmaceuticals AB* (Sweden) |
Toxicological and cGMP- grade protein material |
Resistentia signed a £2M (US$3.16M) manufacturing agreement with Excell covering process development and production of toxicological and cGMP-grade protein material; Resistentia, which is developing a therapeutic vaccine for the treatment for allergy, intends to use the clinical-grade material in Phase I and Phase IIa trials (2/26**) |
|
|||
GeneMax Corp. (OTC BB:GMXX) |
Molecular Medicine BioServices Inc.* |
A clinical vector for delivery of the TAP genes used in GeneMax's lead product |
The contract is based on production of sufficient vaccine to conduct the balance of preclinical work as well as Phase I/II trials (3/19) |
|
|||
GenVec Inc. (GNVC) |
Targeted Genetics Corp. (TGEN) |
Clinical-grade material to supply trials of certain GenVec products |
Contract manufacturing agreement in which Targeted Genetics will conduct initial process feasibility studies in support of the potential manufacturing of clinical-grade materials (4/1) |
|
|
||
Lonza Biologics |
BioReliance Corp. (BREL) |
Viral testing services |
Strategic service level agreement whereby BioReliance is established as a strategic supplier to Lonza of viral testing services for two years (2/27) |
|
|||
Meridian |
Viral Antigens Inc.* |
An insect cell-derived recombinant protein |
Viral Antigens will optimize manufacturing processes and produce a specific insect cell-derived recombinant protein for its contract partner (4/9) |
|
|||
NimbleGen Systems Inc.* |
GeneFrontier Corp.* (Japan) |
Microarray products and services |
NimbleGen appointed GeneFrontier as its exclusive distributor in Japan for customized, ultra-high-density microarray products and services for functional genomics research in Japan and other Asia-Pacific markets (4/4) |
|
|||
OSI Pharmaceuticals Inc. (OSIP) |
Serono SA (Switzerland; NYSE:SRA) |
Novantrone |
Agreement for OSI to market Novantrone in the U.S. for $55M up front; Serono also will receive maintenance fees in return for commissions on net oncology sales (3/12) |
|
|||
Progen Industries Ltd. (Australia; PGLAF) |
Peplin Operations Pty. Ltd. (subsidiary of Peplin Biotech Ltd.; Australia; ASX:PEP) |
PEP 005 |
Contract for the manufacture of Peplin's anti-cancer compound, PEP 005, for clinical trials (3/11) |
|
|||
|
| |||
Notes: | |||
The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange | |||
To read more on related topics, click on one of the words below.